Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEZ235 versus placebo after mTOR inhibitor failure in advanced pancreatic neuroendocrine tumors
NL-OMON37043Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dactolisib in islet cell tumor, sponsored by Novartis. Started Oct 2012; status: active, not recruiting.
02
Drugs
dactolisib
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on NL-OMON37043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37043.